Abstract
The therapy of the idiopathic hypereosinophilic syndrome (HES) is largely directed at controlling symptoms and preventing organ damage. Universally accepted therapeutic protocols for HES are still lacking. Patients are treated by different drugs and drug doses, and therapy appears to be mostly aimed at treating symptoms. However, in order to prevent organ damage the roles of the variously employed agents need to be clarified. Interferon was reported to be an effective agent in 44 patients, and our evaluation of five new cases suggested that IFN-α may be suitable as a first-line therapy.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: January 8, 1998 / Accepted: June 9, 1998
Rights and permissions
About this article
Cite this article
Ceretelli, S., Capochiani, E. & Petrini, M. Interferon-α in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol 77, 161–164 (1998). https://doi.org/10.1007/s002770050434
Issue Date:
DOI: https://doi.org/10.1007/s002770050434